Introduction Apixaban has been shown to be superior to warfarin in patients with non-
valvular atrial fibrillation in the randomized ARISTOTLE trial and its use is recommended in …

Aims Real-world data on treatment persistence, safety and effectiveness of non-Vitamin K
antagonist oral anticoagulants (NOACs) play an important role in the assessment of risks …

Aims It is uncertain whether the benefit from apixaban varies by type and duration of atrial
fibrillation (AF). Methods and results A total of 18 201 patients with AF [2786 (15.3%) with …

Background AVERROES, a randomized controlled trial in high-risk patients with atrial
fibrillation, unsuitable for vitamin K antagonist therapy, demonstrated efficacy and safety of …

The effectiveness and safety of apixaban for stroke prevention in atrial fibrillation (SPAF)
demonstrated in ARISTOTLE needs to be confirmed in daily care. To evaluate effectiveness …

Background Apixaban, a non‐vitamin K oral anticoagulant (NOAC), was approved in Japan
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …

Background The safety and effectiveness of reduced-dose apixaban 2.5 mg twice daily (BID)
have not been elucidated thoroughly in Japanese patients with nonvalvular atrial fibrillation …

Background Apixaban is a non–vitamin K oral anticoagulant approved for prevention of
stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). Current …

Aims To compare the effectiveness and safety of off-label underdosed apixaban with on-
label standard dose apixaban in Asian patients with atrial fibrillation (AF). Methods and …

Objective: To investigate the risk of bleeding events and stroke/systemic embolism (SE)
among Japanese patients with nonvalvular atrial fibrillation (NVAF), focusing on the initial …